One year of treatment with dapirolizumab pegol reduced fatigue and disease activity in people with SLE in a Phase 3 trial.

Researchers have found in a recent meta-analysis that belimumab is more effective than placebo in treating systemic lupus erythematosus (SLE), based on BICLA criteria. This finding ...

Dapirolizumab pegol, a novel CD40L inhibitor, is superior to placebo for achieving low disease activity and remission in ...

DelveInsight's "Systemic Lupus Erythematosus Pipeline Insight, 2025" report delivers comprehensive insights about 120+ companies and 140+ pipeline drugs currently in the various s ...

A novel antibody-based drug targeting the CD40 ligand helped close to half of patients with treatment-refractory systemic ...

Six of the patients, of whom four had non-renal SLE, had follow-up of at least 24 weeks. Of those, five showed dramatic ...

Inflammatory-type lesions and myelopathies found on MRI were significantly associated with attribution of neuropsychiatric events to systemic lupus erythematosus. Magnetic resonance imaging (MRI) ...

Lupus can be debilitating and sometimes deadly for the 3 million people who have it. A treatment called CAR T appears to stop ...

Objective This study aims to evaluate the role of antiphospholipid antibodies (aPLs) in patients with SLE with heart valve ...

A team studied the differences between monogenic and nonmonogenic lupus nephritis and the predictors of end-stage kidney disease.

Dr Li’s team concluded that “patients with SLE-TMA exhibit a progressive decline of patient and renal survival in the long-term. Prompt diagnosis and risk stratification based on identified risk ...